National Eye Institute; Notice of Closed Meeting, 70079 [05-22932]

Download as PDF Federal Register / Vol. 70, No. 223 / Monday, November 21, 2005 / Notices 70079 FEE SCHEDULE JANUARY 1, 2006–SEPTEMBER 30, 2006 Vessel size GRT 1 Extra Small .................................................................................................................................................. Small ............................................................................................................................................................ Medium ........................................................................................................................................................ Large ............................................................................................................................................................ Extra Large .................................................................................................................................................. 1 Gross BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Notice of Approval of Supplemental New Animal Drug Application; Ivermectin and Praziquantel Paste Food and Drug Administration, HHS. ACTION: <3,001 3,001–15,000 15,001–30,000 30,001–60,000 >60,000 1,300 2,600 5,200 7,800 10,400 register tonnage in cubic feet, as shown in Lloyd’s Register of Shipping. Inspections and reinspections involve the same procedure, require the same amount of time, and are therefore charged at the same rate. [FR Doc. 05–22967 Filed 11–18–05; 8:45 am] AGENCY: Fee Notice. SUMMARY: The Food and Drug Administration (FDA) is providing notice that it has approved a supplemental new animal drug application (NADA) filed by Merial, Ltd. The NADA provides for oral use of an ivermectin and praziquantel paste as an over-the-counter product for the treatment and control of various parasitic conditions of horses. This supplemental NADA reduces the minimum age for administration from 5 months to 2 months of age. FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7543, email: melanie.berson@fda.gov. SUPPLEMENTARY INFORMATION: Merial, Ltd., 3239 Satellite Blvd., bldg. 500, Duluth, GA 30096–4640, filed a supplement to NADA 141–214 for ZIMECTERIN GOLD (ivermectin 1.55%/ praziquantel 7.75%) Paste, an over-thecounter product used for the oral treatment and control of various parasitic conditions of horses. This supplemental NADA reduces the minimum age for administration from 5 months to 2 months of age. In accordance with section 512(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(i)) and part 514 (21 CFR part 514) in §§ 514.105(a) and 514.106(a), the Center for Veterinary Medicine is providing notice that this VerDate Aug<31>2005 15:51 Nov 18, 2005 Jkt 208001 supplemental NADA is approved as of October 28, 2005. The basis of approval is discussed in the freedom of information summary. In accordance with the freedom of information provisions of 21 CFR part 20 and § 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. FDA has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required. Dated: November 7, 2005. Steven D. Vaughn, Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. [FR Doc. 05–22941 Filed 11–18–05; 8:45 am] would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel, Gene Therapy Clinical Trial. Date: November 21, 2005. Time: 1 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: Sheraton Gateway Hotel Los Angeles Airport, 6101 W Century Blvd., Los Angeles, CA 90045. Contact Person: Samuel Rawlings, PhD, Chief, Scientific Review Branch, Division of Extramural Research, National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892–9300, 301–451–2020. (Catalogue of Federal Domestic Assistance Program No. 93.867, Vision Research, National Institutes of Health, HHS) Dated: November 14, 2005. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–22932 Filed 11–18–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4160–01–S National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Heart, Lung, and Blood Institute; Notice of Closed Meeting National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, NHLBI. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual grant applications conducted by the National Heart, Lung, and Blood Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Eye Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 Name of Committee: Board of Scientific Counselors, NHLBI. E:\FR\FM\21NON1.SGM 21NON1

Agencies

[Federal Register Volume 70, Number 223 (Monday, November 21, 2005)]
[Notices]
[Page 70079]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-22932]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Eye Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Eye Institute Special Emphasis 
Panel, Gene Therapy Clinical Trial.
    Date: November 21, 2005.
    Time: 1 p.m. to 2 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Sheraton Gateway Hotel Los Angeles Airport, 6101 W 
Century Blvd., Los Angeles, CA 90045.
    Contact Person: Samuel Rawlings, PhD, Chief, Scientific Review 
Branch, Division of Extramural Research, National Eye Institute, 
5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892-9300, 
301-451-2020.

(Catalogue of Federal Domestic Assistance Program No. 93.867, Vision 
Research, National Institutes of Health, HHS)


    Dated: November 14, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-22932 Filed 11-18-05; 8:45 am]
BILLING CODE 4140-01-M
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.